27464574|t|Objective Assessment of Vergence after Treatment of Concussion - Related CI: A Pilot Study
27464574|a|To evaluate changes in objective measures of disparity vergence after office-based vision therapy (OBVT) for concussion - related convergence insufficiency (CI) and determine the feasibility of using this objective assessment as an outcome measure in a clinical trial. This was a prospective, observational trial. All participants were treated with weekly OBVT with home reinforcement. Participants included two adolescents and three young adults with concussion - related, symptomatic CI. The primary outcome measure was average peak velocity for 4° symmetrical convergence steps. Other objective outcome measures of disparity vergence included time to peak velocity, latency, accuracy, settling time, and main sequence. We also evaluated saccadic eye movements using the same outcome measures. Changes in clinical measures (near point of convergence, positive fusional vergence at near, Convergence Insufficiency Symptom Survey [CISS] score) were evaluated. There were statistically significant and clinically meaningful changes in all clinical measures for convergence. Four of the five subjects met clinical success criteria. For the objective measures, we found a statistically significant increase in peak velocity, response accuracy to 4° symmetrical convergence and divergence step stimuli, and the main sequence ratio for convergence step stimuli. Objective saccadic eye movements (5 and 10°) appeared normal pre- OBVT and did not show any significant change after treatment. This is the first report of the use of objective measures of disparity vergence as outcome measures for concussion - related convergence insufficiency. These measures provide additional information that is not accessible with clinical tests about underlying physiological mechanisms leading to changes in clinical findings and symptoms. The study results also demonstrate that patients with concussion can tolerate the visual demands (over 200 vergence and versional eye movements) during the 25-minute testing time and suggest that these measures could be used in a large-scale randomized clinical trial of concussion - related CI as outcome measures.
27464574	0	9	Objective	T080	C1571702
27464574	10	20	Assessment	T058	C0220825
27464574	24	32	Vergence	T042	C0678898
27464574	39	48	Treatment	T061	C0087111
27464574	52	62	Concussion	T037	C0006107
27464574	65	72	Related	T080	C0439849
27464574	73	75	CI	T047	C0271379
27464574	79	90	Pilot Study	T062	C0031928
27464574	94	102	evaluate	T058	C0220825
27464574	103	110	changes	T081	C0443172
27464574	114	123	objective	T080	C1571702
27464574	124	132	measures	T081	C0079809
27464574	136	154	disparity vergence	T081	C0042791
27464574	161	188	office-based vision therapy	T061	C0150177
27464574	190	194	OBVT	T061	C0150177
27464574	200	210	concussion	T037	C0006107
27464574	213	220	related	T080	C0439849
27464574	221	246	convergence insufficiency	T047	C0271379
27464574	248	250	CI	T047	C0271379
27464574	270	281	feasibility	T062,T170	C0015730
27464574	296	305	objective	T080	C1571702
27464574	306	316	assessment	T058	C0220825
27464574	323	338	outcome measure	T081	C0086749
27464574	344	358	clinical trial	T062	C0008976
27464574	371	382	prospective	T080	C0205556
27464574	384	403	observational trial	T062	C1518527
27464574	409	421	participants	T098	C0679646
27464574	427	439	treated with	T061	C0332293
27464574	440	446	weekly	T079	C0332174
27464574	447	451	OBVT	T061	C0150177
27464574	457	461	home	T082	C0442519
27464574	462	475	reinforcement	T061	C1283081
27464574	477	489	Participants	T098	C0679646
27464574	490	498	included	T169	C0332257
27464574	503	514	adolescents	T100	C0205653
27464574	525	537	young adults	T100	C0238598
27464574	543	553	concussion	T037	C0006107
27464574	556	563	related	T080	C0439849
27464574	565	576	symptomatic	T169	C0231220
27464574	577	579	CI	T047	C0271379
27464574	585	608	primary outcome measure	T080	C3274433
27464574	613	620	average	T081	C1510992
27464574	621	634	peak velocity	T033	C0243095
27464574	642	653	symmetrical	T033	C0332516
27464574	654	665	convergence	T042	C0870533
27464574	679	688	objective	T080	C1571702
27464574	689	705	outcome measures	T081	C0086749
27464574	709	727	disparity vergence	T081	C0042791
27464574	728	736	included	T169	C0332257
27464574	737	741	time	T079	C0040223
27464574	745	758	peak velocity	T033	C0243095
27464574	760	767	latency	T079	C0242465
27464574	769	777	accuracy	T080	C0443131
27464574	779	792	settling time	T079	C0040223
27464574	803	811	sequence	T169	C1519249
27464574	821	830	evaluated	T058	C0220825
27464574	831	853	saccadic eye movements	T042	C0036019
27464574	869	885	outcome measures	T081	C0086749
27464574	887	894	Changes	T081	C0443172
27464574	898	915	clinical measures	T033	C3266594
27464574	917	942	near point of convergence	T047	C0423037
27464574	944	952	positive	T033	C1514241
27464574	953	978	fusional vergence at near	T042	C1302986
27464574	980	1020	Convergence Insufficiency Symptom Survey	T170	C0282574
27464574	1022	1026	CISS	T170	C0282574
27464574	1028	1033	score	T081	C0449820
27464574	1040	1049	evaluated	T058	C0220825
27464574	1062	1087	statistically significant	T081	C0237881
27464574	1092	1102	clinically	T080	C0205210
27464574	1103	1113	meaningful	T080	C0205556
27464574	1114	1121	changes	T081	C0443172
27464574	1129	1146	clinical measures	T033	C3266594
27464574	1151	1162	convergence	T042	C0870533
27464574	1181	1189	subjects	T098	C2349001
27464574	1194	1202	clinical	T080	C0205210
27464574	1203	1210	success	T080	C0679864
27464574	1211	1219	criteria	T078	C0243161
27464574	1229	1238	objective	T080	C1571702
27464574	1239	1247	measures	T081	C0079809
27464574	1260	1285	statistically significant	T081	C0237881
27464574	1286	1294	increase	T081	C0205217
27464574	1298	1311	peak velocity	T033	C0243095
27464574	1313	1321	response	T032	C0871261
27464574	1322	1330	accuracy	T080	C0443131
27464574	1337	1348	symmetrical	T033	C0332516
27464574	1349	1360	convergence	T042	C0870533
27464574	1365	1375	divergence	T082	C0443204
27464574	1381	1388	stimuli	T067	C0234402
27464574	1403	1417	sequence ratio	T081	C1709842
27464574	1422	1433	convergence	T042	C0870533
27464574	1439	1446	stimuli	T067	C0234402
27464574	1448	1457	Objective	T080	C1571702
27464574	1458	1480	saccadic eye movements	T042	C0036019
27464574	1502	1508	normal	T080	C0205307
27464574	1514	1518	OBVT	T061	C0150177
27464574	1540	1551	significant	T078	C0750502
27464574	1552	1558	change	T081	C0443172
27464574	1565	1574	treatment	T061	C0087111
27464574	1594	1600	report	T170	C0684224
27464574	1615	1624	objective	T080	C1571702
27464574	1625	1633	measures	T081	C0079809
27464574	1637	1655	disparity vergence	T081	C0042791
27464574	1659	1675	outcome measures	T081	C0086749
27464574	1680	1690	concussion	T037	C0006107
27464574	1693	1700	related	T080	C0439849
27464574	1701	1726	convergence insufficiency	T047	C0271379
27464574	1734	1742	measures	T081	C0079809
27464574	1751	1761	additional	T169	C1524062
27464574	1762	1773	information	T078	C1533716
27464574	1786	1796	accessible	T082	C0444454
27464574	1802	1816	clinical tests	T059	C0022885
27464574	1834	1847	physiological	T169	C0205463
27464574	1848	1858	mechanisms	T169	C0441712
27464574	1870	1877	changes	T081	C0443172
27464574	1881	1898	clinical findings	T184	C0037088
27464574	1903	1911	symptoms	T184	C1457887
27464574	1917	1922	study	T062	C2603343
27464574	1923	1930	results	T034	C0456984
27464574	1953	1961	patients	T101	C0030705
27464574	1967	1977	concussion	T037	C0006107
27464574	1995	2001	visual	T169	C0234621
27464574	2002	2009	demands	T061	C0441516
27464574	2020	2028	vergence	T042	C0678898
27464574	2033	2042	versional	T080	C0205556
27464574	2043	2056	eye movements	T039	C0015413
27464574	2079	2091	testing time	T079	C0429928
27464574	2096	2103	suggest	T078	C1705535
27464574	2115	2123	measures	T081	C0079809
27464574	2143	2154	large-scale	UnknownType	C0814860
27464574	2155	2180	randomized clinical trial	T062,T170	C0206034
27464574	2184	2194	concussion	T037	C0006107
27464574	2197	2204	related	T080	C0439849
27464574	2205	2207	CI	T047	C0271379
27464574	2211	2227	outcome measures	T081	C0086749